the responsibility for enforcement. They disagreed with the concept 
of voluntary compliance citing the lack of evidence in other areas 
for such willingness by American industry. They believed regulations 
with provisions for penalties were required with the final respon- 
sibility resting in 06HA. A representative of the Pharmaceutical 
Manufacturers Association (PMA) expressed his industry's willingness 
to comply with the Guidelines providing provision could be made 
for preservation of trade secrets. Other witnesses suggested mandating 
the composition of the insti tutional biohazard committees, public 
representation on the RAC, and on-site inspections by NIH when 
necessary. 
Conc lusion 
In the discussion period each member of the DAC summarized 
his or her viewpoint. The issues addressed included training of 
laboratory personnel, collection of data on the incidence of laboratory 
infections, public representation on institutional biohazard committees, 
and the need for more risk assessment studies. Dr. Fredrickson closed 
the meeting by requesting more detailed written comments from each 
of the participants. 
xiii 
[ 199 ] 
